Moderna (MRNA) Stock Price & Analysis

MRNA$223.37-7.98 -3.45%
BiotechnologyLarge Cap
Compare
Market cap$90.38BEnterprise value$102.72BRevenue (TTM)$2.23BMarket positionTop 25%

Score

24
Bearish
Value
44
Quality
27
Growth
0

AI Analysis

Snapshot

Moderna doesn’t screen as a clean setup today — Stocklytics 24/100 leaves more to prove. Under the hood: revenue compounding ~-52% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

44
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

0
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

27
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Moderna, Inc. (MRNA) last printed $223.37. Equity value is $90.38B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$108.4M$205.82M$135.07M$60.21M$803.39M$17.74B$18.88B$6.85B$3.2B$1.94B

About

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Moderna (MRNA) Stock Price & Analysis

MRNA price $223.37 -7.98 -3.45%

Ticker
MRNA
Price
$223.37
Change
-7.98 -3.45%
Market cap
$90.38B
Dividend yield
0.00%
Beta
0.90
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
24
Value
44
Quality
27
Growth
0

Stocklytics score rationale: value 44, quality 27, growth 0.

AI Score 35. Moderna, Inc. has a high price-to-sales ratio of approximately 46.3 and negative profit margins, with a net profit margin of -1.41

Insights · Forecast · Financials · Learn

Stocklytics home · Screener